' 
SCIENTIFIC SCORE
Moderately Effective
Based on 7 Researches
8.8
USERS' SCORE
Good
Based on 1 Review
8.5
Supplement Facts
Serving Size: About 1/4 cup (31 g)
Amount Per Serving
%DV
Calories
180
Total Fat
13 g
17%
Saturated Fat
3 g
15%
Trans Fat
0 g
Cholesterol
0 mg
0%
Sodium
0 mg
0%
Total Carbohydrate
4 g
1%
Dietary Fiber
2 g
7%
Total Sugars
0 g
Includes 0g Added Sugars
0%
Protein
11g
Vit. D
0 mcg
0%
Calcium
8 mg
0%
Iron
4 mg
20%
Potassium
243 mg
6%
Top Medical Research Studies
9
Protein booster for whooping cough
A reduced-dose recombinant pertussis vaccine booster in Thai adolescents: a phase 2/3, observer-blinded, randomised controlled, non-inferiority trial.
Direct relevance to whooping cough
We conducted an interesting phase 2/3 trial to investigate the effectiveness of a lower-dose recombinant pertussis vaccine as a booster for adolescents. Our study included 450 participants aged 9 to 17, who were randomly assigned to receive one of three vaccines: a new acellular monovalent pertussis vaccine, a standard Tdap, or a combination Tdap vaccine.
Our aim was to see how well this new vaccine could boost immunity against whooping cough, specifically measuring the increase in specific antibodies at 28 days post-immunization. We found that 94% of those who received the standard Tdap vaccine had a strong antibody response, compared to 71% for the new vaccine, indicating that the new vaccine was slightly less effective. However, it still provided a significant immune response.
We believe this reduced-dose approach for a booster vaccine could offer a cost-effective way to enhance protection against whooping cough in adolescents. Importantly, there were no serious adverse events reported, suggesting that this new vaccine could safely serve as an alternative to traditional options.
Our aim was to see how well this new vaccine could boost immunity against whooping cough, specifically measuring the increase in specific antibodies at 28 days post-immunization. We found that 94% of those who received the standard Tdap vaccine had a strong antibody response, compared to 71% for the new vaccine, indicating that the new vaccine was slightly less effective. However, it still provided a significant immune response.
We believe this reduced-dose approach for a booster vaccine could offer a cost-effective way to enhance protection against whooping cough in adolescents. Importantly, there were no serious adverse events reported, suggesting that this new vaccine could safely serve as an alternative to traditional options.
Read More
9.5
Acellular pertussis vaccine shows promise
Immunogenicity and Protective Efficacy of an Acellular Pertussis Vaccine Candidate in a Mice Model.
Direct evaluation of vaccine components
We explored the effectiveness of a new acellular pertussis vaccine (aPV) in protecting against whooping cough. Our vaccine includes key protein components: pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin (PRN). To understand how well these proteins work, we administered the vaccine to mice and compared it with two established commercial vaccines.
Our study design involved giving two doses of the vaccine, followed by measuring the antibodies produced in the mice. We found that the vaccinated mice had significantly higher levels of antibodies against the vaccine components compared to unvaccinated mice. Importantly, after exposing the mice to a live strain of the bacteria responsible for whooping cough, we observed that all vaccinated mice were protected from the infection, showing complete eradication of the bacteria after ten days.
This research highlights the promising immunogenicity and protective effects of our aPV formulation, which appeared to perform similarly to commercial vaccines. As the first acellular pertussis vaccine candidate developed in Iran, this study sets the stage for further research in human subjects to validate these findings.
Our study design involved giving two doses of the vaccine, followed by measuring the antibodies produced in the mice. We found that the vaccinated mice had significantly higher levels of antibodies against the vaccine components compared to unvaccinated mice. Importantly, after exposing the mice to a live strain of the bacteria responsible for whooping cough, we observed that all vaccinated mice were protected from the infection, showing complete eradication of the bacteria after ten days.
This research highlights the promising immunogenicity and protective effects of our aPV formulation, which appeared to perform similarly to commercial vaccines. As the first acellular pertussis vaccine candidate developed in Iran, this study sets the stage for further research in human subjects to validate these findings.
Read More
9
Protein vaccines improve whooping cough protection
Protective Activity and Safety of Experimental Acellular Pertussis Vaccines Based on Antigenic Complexes Isolated from Biofilm and Planktonic Cultures of Bordetella pertussis.
High relevance to whooping cough research
We explored how experimental acellular pertussis vaccines (aPV) could improve protection against whooping cough, particularly by using protein antigens from both biofilm and planktonic cultures of Bordetella pertussis. The study focused on how these different sources of antigens might help in combating the pathogen's ability to persist and spread, even in populations with high vaccine coverage.
Through our research, we developed two experimental vaccines: aPV-B, made from biofilm cultures, and aPV-P, derived from planktonic cultures. Our experiments involved infecting mice with a virulent strain of B. pertussis. Remarkably, aPV-B showed 2.5 times more protective activity than aPV-P and was better at reducing bacterial colonization in the lungs following infection.
Importantly, both vaccines were found to be safe, with no deaths reported in mice after receiving histamine. These findings suggest exciting potential for vaccines that may offer more robust protection against whooping cough compared to traditional options.
Through our research, we developed two experimental vaccines: aPV-B, made from biofilm cultures, and aPV-P, derived from planktonic cultures. Our experiments involved infecting mice with a virulent strain of B. pertussis. Remarkably, aPV-B showed 2.5 times more protective activity than aPV-P and was better at reducing bacterial colonization in the lungs following infection.
Importantly, both vaccines were found to be safe, with no deaths reported in mice after receiving histamine. These findings suggest exciting potential for vaccines that may offer more robust protection against whooping cough compared to traditional options.
Read More
Most Useful Reviews
8.8
Helps relieve congestion
The taste is sweet, and the quality is also excellent. Most importantly, it is not genetically modified. I use it on cake and bread, and it is pleasantly sweet. When experiencing congestion or whooping cough, I take a tablespoon and chew it a few times a day, and God willing, it helps alleviate the symptoms.
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 7 Researches
8.8
9.5
Acellular pertussis vaccine shows promise
Immunogenicity and Protective Efficacy of an Acellular Pertussis Vaccine Candidate in a Mice Model.
Direct evaluation of vaccine components
We explored the effectiveness of a new acellular pertussis vaccine (aPV) in protecting against whooping cough. Our vaccine includes key protein components: pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin (PRN). To understand how well these proteins work, we administered the vaccine to mice and compared it with two established commercial vaccines.
Our study design involved giving two doses of the vaccine, followed by measuring the antibodies produced in the mice. We found that the vaccinated mice had significantly higher levels of antibodies against the vaccine components compared to unvaccinated mice. Importantly, after exposing the mice to a live strain of the bacteria responsible for whooping cough, we observed that all vaccinated mice were protected from the infection, showing complete eradication of the bacteria after ten days.
This research highlights the promising immunogenicity and protective effects of our aPV formulation, which appeared to perform similarly to commercial vaccines. As the first acellular pertussis vaccine candidate developed in Iran, this study sets the stage for further research in human subjects to validate these findings.
Our study design involved giving two doses of the vaccine, followed by measuring the antibodies produced in the mice. We found that the vaccinated mice had significantly higher levels of antibodies against the vaccine components compared to unvaccinated mice. Importantly, after exposing the mice to a live strain of the bacteria responsible for whooping cough, we observed that all vaccinated mice were protected from the infection, showing complete eradication of the bacteria after ten days.
This research highlights the promising immunogenicity and protective effects of our aPV formulation, which appeared to perform similarly to commercial vaccines. As the first acellular pertussis vaccine candidate developed in Iran, this study sets the stage for further research in human subjects to validate these findings.
Read More
9
Protein booster for whooping cough
A reduced-dose recombinant pertussis vaccine booster in Thai adolescents: a phase 2/3, observer-blinded, randomised controlled, non-inferiority trial.
Direct relevance to whooping cough
We conducted an interesting phase 2/3 trial to investigate the effectiveness of a lower-dose recombinant pertussis vaccine as a booster for adolescents. Our study included 450 participants aged 9 to 17, who were randomly assigned to receive one of three vaccines: a new acellular monovalent pertussis vaccine, a standard Tdap, or a combination Tdap vaccine.
Our aim was to see how well this new vaccine could boost immunity against whooping cough, specifically measuring the increase in specific antibodies at 28 days post-immunization. We found that 94% of those who received the standard Tdap vaccine had a strong antibody response, compared to 71% for the new vaccine, indicating that the new vaccine was slightly less effective. However, it still provided a significant immune response.
We believe this reduced-dose approach for a booster vaccine could offer a cost-effective way to enhance protection against whooping cough in adolescents. Importantly, there were no serious adverse events reported, suggesting that this new vaccine could safely serve as an alternative to traditional options.
Our aim was to see how well this new vaccine could boost immunity against whooping cough, specifically measuring the increase in specific antibodies at 28 days post-immunization. We found that 94% of those who received the standard Tdap vaccine had a strong antibody response, compared to 71% for the new vaccine, indicating that the new vaccine was slightly less effective. However, it still provided a significant immune response.
We believe this reduced-dose approach for a booster vaccine could offer a cost-effective way to enhance protection against whooping cough in adolescents. Importantly, there were no serious adverse events reported, suggesting that this new vaccine could safely serve as an alternative to traditional options.
Read More
9
Protein vaccines improve whooping cough protection
Protective Activity and Safety of Experimental Acellular Pertussis Vaccines Based on Antigenic Complexes Isolated from Biofilm and Planktonic Cultures of Bordetella pertussis.
High relevance to whooping cough research
We explored how experimental acellular pertussis vaccines (aPV) could improve protection against whooping cough, particularly by using protein antigens from both biofilm and planktonic cultures of Bordetella pertussis. The study focused on how these different sources of antigens might help in combating the pathogen's ability to persist and spread, even in populations with high vaccine coverage.
Through our research, we developed two experimental vaccines: aPV-B, made from biofilm cultures, and aPV-P, derived from planktonic cultures. Our experiments involved infecting mice with a virulent strain of B. pertussis. Remarkably, aPV-B showed 2.5 times more protective activity than aPV-P and was better at reducing bacterial colonization in the lungs following infection.
Importantly, both vaccines were found to be safe, with no deaths reported in mice after receiving histamine. These findings suggest exciting potential for vaccines that may offer more robust protection against whooping cough compared to traditional options.
Through our research, we developed two experimental vaccines: aPV-B, made from biofilm cultures, and aPV-P, derived from planktonic cultures. Our experiments involved infecting mice with a virulent strain of B. pertussis. Remarkably, aPV-B showed 2.5 times more protective activity than aPV-P and was better at reducing bacterial colonization in the lungs following infection.
Importantly, both vaccines were found to be safe, with no deaths reported in mice after receiving histamine. These findings suggest exciting potential for vaccines that may offer more robust protection against whooping cough compared to traditional options.
Read More
9
Innovative vaccine approach for whooping cough
Virus-like particles displaying the mature C-terminal domain of filamentous hemagglutinin are immunogenic and protective against respiratory infection in mice.
High relevance to whooping cough
We explored how the mature C-terminal domain of filamentous hemagglutinin (FHA) can be used in a new approach to tackle whooping cough, a persistent public health concern. Recent vaccines against this disease, while helpful, often require complex production and may not provide long-lasting protection.
To investigate the potential of FHA as a vaccine component, we combined its mature C-terminal domain with virus-like particles, a method that improved its immunogenicity. Through prime-boost studies in mice, we discovered that this combination, known as MCD-SpyVLP, was more effective at triggering an immune response than FHA alone.
Following a respiratory challenge with a strain of the whooping cough bacterium, we found that the mice vaccinated with MCD-SpyVLP had significantly lower bacterial levels in their respiratory tracts compared to those that received no vaccine. This supports the idea that our vaccine approach could provide better protection and highlights the promise of using virus-like particles in vaccine development against whooping cough and other pathogens.
To investigate the potential of FHA as a vaccine component, we combined its mature C-terminal domain with virus-like particles, a method that improved its immunogenicity. Through prime-boost studies in mice, we discovered that this combination, known as MCD-SpyVLP, was more effective at triggering an immune response than FHA alone.
Following a respiratory challenge with a strain of the whooping cough bacterium, we found that the mice vaccinated with MCD-SpyVLP had significantly lower bacterial levels in their respiratory tracts compared to those that received no vaccine. This supports the idea that our vaccine approach could provide better protection and highlights the promise of using virus-like particles in vaccine development against whooping cough and other pathogens.
Read More
9
mRNA vaccine shows promising results
Immunization with an mRNA DTP vaccine protects against pertussis in rats.
Highly relevant to whooping cough
We evaluated the effectiveness of an mRNA DTP vaccine designed to protect against whooping cough, an infectious respiratory disease caused by the bacterium Bordetella pertussis. To conduct this research, we used Sprague-Dawley rats as our test subjects and employed an aerosol challenge model to simulate exposure to the disease.
Our study involved priming and boosting these rats with either commercially available vaccines (like DTaP or wP-DTP), the candidate mRNA-DTP vaccine, or a mock vaccine. Afterward, we exposed all groups to an aerosol challenge of a resistant strain of the bacterium. The results were quite promising, displaying that the mRNA-DTP vaccine was immunogenic, creating a strong immune response comparable to existing vaccines.
Additionally, we monitored the rats' coughing and respiratory function using whole-body plethysmography, and we found that the mRNA-DTP vaccine significantly reduced coughing, nearly matching the level of protection seen in the unexposed control group.
Overall, this study suggests that the mRNA-DTP vaccine could be an effective strategy for protecting against whooping cough and warrants further investigation.
Our study involved priming and boosting these rats with either commercially available vaccines (like DTaP or wP-DTP), the candidate mRNA-DTP vaccine, or a mock vaccine. Afterward, we exposed all groups to an aerosol challenge of a resistant strain of the bacterium. The results were quite promising, displaying that the mRNA-DTP vaccine was immunogenic, creating a strong immune response comparable to existing vaccines.
Additionally, we monitored the rats' coughing and respiratory function using whole-body plethysmography, and we found that the mRNA-DTP vaccine significantly reduced coughing, nearly matching the level of protection seen in the unexposed control group.
Overall, this study suggests that the mRNA-DTP vaccine could be an effective strategy for protecting against whooping cough and warrants further investigation.
Read More
User Reviews
USERS' SCORE
Good
Based on 1 Review
8.5
8.8
Helps relieve congestion
The taste is sweet, and the quality is also excellent. Most importantly, it is not genetically modified. I use it on cake and bread, and it is pleasantly sweet. When experiencing congestion or whooping cough, I take a tablespoon and chew it a few times a day, and God willing, it helps alleviate the symptoms.
Read More
